Stock Scorecard
Stock Summary for T2 Biosystems Inc (TTOO) - $2.99 as of 4/18/2024 10:51:06 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TTOO
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TTOO
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TTOO
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for TTOO
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for TTOO
Financial Details for TTOO
Company Overview |
|
---|---|
Ticker | TTOO |
Company Name | T2 Biosystems Inc |
Country | USA |
Description | T2 Biosystems, Inc., an in vitro diagnostic company, develops diagnostic products and candidate products in the United States and internationally. The company is headquartered in Lexington, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Most Recent Quarter | 3/31/2024 |
Next Earnings Date | 5/21/2024 |
Stock Price History |
|
Last Day Price | 2.99 |
Last Day Price Updated | 4/18/2024 10:51:06 PM EST |
Last Day Volume | 106,827 |
Average Daily Volume | 193,766 |
52-Week High | 70.00 |
52-Week Low | 2.70 |
Last Price to 52 Week Low | 10.74% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 48.25 |
Sector PE | 61.34 |
5-Year Average PE | -90.63 |
Free Cash Flow Ratio | 1.05 |
Industry Free Cash Flow Ratio | 61.76 |
Sector Free Cash Flow Ratio | 30.17 |
Current Ratio Most Recent Quarter | 0.45 |
Total Cash Per Share | 2.85 |
Book Value Per Share Most Recent Quarter | -6.91 |
Price to Book Ratio | 14.50 |
Industry Price to Book Ratio | 5.21 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 2.41 |
Industry Price to Sales Ratio Twelve Trailing Months | 14.23 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 5,512,300 |
Market Capitalization | 16,481,777 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 19.23% |
Reported EPS 12 Trailing Months | -19.19 |
Reported EPS Past Year | -3.96 |
Reported EPS Prior Year | -7.40 |
Net Income Twelve Trailing Months | -50,077,000 |
Net Income Past Year | -50,077,000 |
Net Income Prior Year | -62,003,000 |
Quarterly Revenue Growth YOY | -69.40% |
5-Year Revenue Growth | -7.24% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 15,689,000 |
Total Cash Past Year | 15,689,000 |
Total Cash Prior Year | 10,329,000 |
Net Cash Position Most Recent Quarter | -25,459,000 |
Net Cash Position Past Year | -25,459,000 |
Long Term Debt Past Year | 41,148,000 |
Long Term Debt Prior Year | 49,496,000 |
Total Debt Most Recent Quarter | 41,148,000 |
Equity to Debt Ratio Past Year | -2.13 |
Equity to Debt Ratio Most Recent Quarter | -2.13 |
Total Stockholder Equity Past Year | -28,000,000 |
Total Stockholder Equity Prior Year | -39,655,000 |
Total Stockholder Equity Most Recent Quarter | -28,000,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.31 |
MACD Signal | -0.39 |
20-Day Bollinger Lower Band | 2.32 |
20-Day Bollinger Middle Band | 4.37 |
20-Day Bollinger Upper Band | 6.41 |
Beta | 0.10 |
RSI | 37.40 |
50-Day SMA | 13.16 |
200-Day SMA | 2,926.48 |
System |
|
Modified | 4/18/2024 1:40:24 PM EST |